B · Normal
On September 30th, AbbVie announced that its drug under development, ABBV-295, showed a weight loss effect of up to 9.8% in a phase 1 clinical trial, showing "meaningful weight loss."
Related telegraphs
[Balitianheng: The first subject has been enrolled in the T-Bren phase III clini
09-29 18:54
[Lepu Medical: Subsidiary MWN110 injection has been approved for clinical trials
09-28 18:39
[Hisco: Innovative drug HSK42360-Na tablets are included in the Breakthrough The
09-27 15:51
[Chengda Biotech: Signed Recombinant Tetravalent Enterovirus Vaccine Technology
09-24 17:20
September 23rd, Novo Nordisk is reported to be considering upgrading its New Yor
09-23 12:03
[Four-connected Nanhua Bio: Cell therapy-related technologies and products are s
09-22 18:20
Comments